Suppr超能文献

中国非小细胞肺癌患者中致病种系/突变的患病率及临床意义

Prevalence and clinical significance of pathogenic germline / mutations in Chinese non-small cell lung cancer patients.

作者信息

Hu Xingsheng, Yang Dongyong, Li Yalun, Li Li, Wang Yan, Chen Peng, Xu Song, Pu Xingxiang, Zhu Wei, Deng Pengbo, Ye Junyi, Zhang Hanhan, Lizaso Analyn, Liu Hao, Mao Xinru, Huang Hai, Chu Qian, Hu Chengping

机构信息

Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.

Department of Pulmonary Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou 362100, China.

出版信息

Cancer Biol Med. 2019 Aug;16(3):556-564. doi: 10.20892/j.issn.2095-3941.2018.0506.

Abstract

OBJECTIVE

Germline alterations in the breast cancer susceptibility genes type 1 and 2, and , predispose individuals to hereditary cancers, including breast, ovarian, prostate, pancreatic, and stomach cancers. Accumulating evidence suggests inherited genetic susceptibility to lung cancer. The present study aimed to survey the prevalence of pathogenic germline mutations () and explore the potential association between and disease onset in Chinese advanced non-small cell lung cancer (NSCLC) patients.

METHODS

A total of 6,220 NSCLC patients were screened using capture-based ultra-deep targeted sequencing to identify patients harboring germline / mutations.

RESULTS

Out of the 6,220 patients screened, 1.03% (64/6,220) of the patients harbored the pathogenic , with mutations being the most pr edominant mutations (49/64, 76.5%). Patients who developed NSCLC before 50 years of age were more likely to carry ( = 0.036). Among the patients harboring classic lung cancer driver mutations, those with concurrent were significantly younger than those harboring the wild-type ( = 0.029). By contrast, the age of patients with or without concurrent was comparable to those of patients without the driver mutations ( = 0.972). In addition, we identified -mutant patients with concurrent g who showed comparable progression-free survival but significantly longer overall survival ( = 0.002) compared to -mutant patients with wild-type germline .

CONCLUSIONS

Overall, our study is the largest survey of the prevalence of pathogenic in advanced Chinese NSCLC patients. Results suggested a lack of association between germline status and treatment outcome of EGFR-TKI. In addition, results showed a positive correlation between pathogenic and an early onset of NSCLC.

摘要

目的

乳腺癌易感基因1和2(BRCA1和BRCA2)的种系改变使个体易患遗传性癌症,包括乳腺癌、卵巢癌、前列腺癌、胰腺癌和胃癌。越来越多的证据表明存在肺癌的遗传易感性。本研究旨在调查中国晚期非小细胞肺癌(NSCLC)患者中致病性种系BRCA1/2突变(BRCAm)的发生率,并探讨BRCAm与疾病发病之间的潜在关联。

方法

共6220例NSCLC患者接受基于捕获的超深度靶向测序,以识别携带种系BRCA1/2突变的患者。

结果

在6220例接受筛查的患者中,1.03%(64/6220)的患者携带致病性BRCAm,其中BRCA2突变是最主要的突变类型(49/64,76.5%)。50岁之前发生NSCLC的患者更有可能携带BRCAm(P=0.036)。在携带经典肺癌驱动基因突变的患者中,同时携带BRCAm的患者明显比携带野生型BRCA的患者年轻(P=0.029)。相比之下,有或无BRCAm的患者年龄与无驱动基因突变的患者相当(P=0.972)。此外,我们发现携带BRCAm同时伴有胚系TP53突变的患者与携带野生型胚系BRCA的BRCAm突变患者相比,无进展生存期相当,但总生存期明显更长(P=0.002)。

结论

总体而言,我们的研究是对中国晚期NSCLC患者致病性BRCAm发生率的最大规模调查。结果表明种系BRCA状态与EGFR-TKI治疗结果之间缺乏关联。此外,结果显示致病性BRCAm与NSCLC的早发之间存在正相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63ce/6743617/b1870ac6e6c9/cbm-16-3-556-S1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验